95119-86-1
Chemical Structure
GlcCer (d18:1/18:0)
Synonym(s): C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine
- CAS No.: 95119-86-1
- Formula:C42H81NO8
- Molecular Weight:728.09
InChIKey: YMYQEDCYNANIPI-DYJXBSQNSA-N
SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCCCC)=O)CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO
Biological Activity: GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GlcCer (d18:1/18:0) | 99.93% | GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18 Glucosyl(ß) ceramide-d5 | 99% | C18 Glucosyl(ß) ceramide-d5 is deuterium labeled C18 Glucosyl(ß) ceramide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Qiu Z, et al. GBA1-dependent membrane glucosylceramide reprogramming promotes liver cancer metastasis via activation of the Wnt/β-catenin signalling pathway. Cell Death Dis. 2022;13(5):508. Published 2022 May 30. [Content Brief]
- [2]. Lerche S, et al. CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants. NPJ Parkinsons Dis. 2024;10(1):198. Published 2024 Oct 24. [Content Brief]
- [3]. Zhu C, et al. Glucosylceramides are required for mycelial growth and full virulence in Penicillium digitatum. Biochem Biophys Res Commun. 2014;455(3-4):165-171. [Content Brief]
- [4]. Zhao Z, et al. Untargeted Metabolomic Profiling of Cuprizone-Induced Demyelination in Mouse Corpus Callosum by UPLC-Orbitrap/MS Reveals Potential Metabolic Biomarkers of CNS Demyelination Disorders. Oxid Med Cell Longev. 2021;2021:7093844. Published 2021 Sep 14. [Content Brief]
